Bicara Therapeutics (BCAX) CEO sells 15,000 shares after option exercise

Rhea-AI Filing Summary

Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised stock options and sold the related shares over three days. She exercised options for a total of 15,000 shares of Common Stock at an exercise price of $3.7898 per share, then sold 15,000 shares in open-market transactions at weighted-average prices between $18.73 and $19.26, as disclosed in the price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following the transactions, she holds 339,392 shares of Common Stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar Claire

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		M(1)		6,499	A	$3.7898	345,891	D
Common Stock	03/18/2026		S(1)		6,499	D	$18.8359(2)	339,392	D
Common Stock	03/19/2026		M(1)		6,905	A	$3.7898	346,297	D
Common Stock	03/19/2026		S(1)		6,905	D	$18.7842(3)	339,392	D
Common Stock	03/20/2026		M(1)		1,596	A	$3.7898	340,988	D
Common Stock	03/20/2026		S(1)		1,596	D	$18.9513(4)	339,392	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7898	03/18/2026		M(1)			6,499	(5)	08/08/2033	Common Stock	6,499	$0	184,608	D
Stock Option (Right to Buy)	$3.7898	03/19/2026		M(1)			6,905	(5)	08/08/2033	Common Stock	6,905	$0	177,703	D
Stock Option (Right to Buy)	$3.7898	03/20/2026		M(1)			1,596	(5)	08/08/2033	Common Stock	1,596	$0	176,107	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

5. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bicara Therapeutics (BCAX) CEO Claire Mazumdar report in this Form 4?

Claire Mazumdar reported exercising stock options for 15,000 Bicara Therapeutics shares and selling 15,000 shares in the open market. The filing reflects a routine exercise-and-sell pattern tied to existing options rather than a new open-market share purchase.

How many Bicara Therapeutics (BCAX) shares did the CEO sell, and at what prices?

The CEO sold 15,000 shares of Bicara Therapeutics Common Stock in multiple open-market transactions. Weighted-average sale prices fell within disclosed ranges between $18.73 and $19.26 per share, with detailed breakdowns available upon request from the issuer or the SEC staff.

What options did the Bicara Therapeutics (BCAX) CEO exercise in this filing?

She exercised stock options covering 15,000 underlying Bicara Therapeutics Common shares at an exercise price of $3.7898 per share. These options are part of a grant that vests in sixteen equal quarterly installments following August 8, 2023, contingent on continued service.

How many Bicara Therapeutics (BCAX) shares does the CEO hold after these transactions?

After completing the option exercises and related sales, the CEO directly holds 339,392 shares of Bicara Therapeutics Common Stock. This post-transaction ownership figure comes from the Form 4 totals reported following the final sale transaction in the series.

Were the Bicara Therapeutics (BCAX) CEO’s share sales made under a Rule 10b5-1 plan?

Yes. The filing states that at least one of the reported transactions was executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Such plans pre-schedule trades, reducing the significance of trade timing for interpreting insider sentiment.

Do these Bicara Therapeutics (BCAX) Form 4 transactions indicate an ongoing derivative position?

The transactions show exercises of stock options that expire in 2033 and corresponding sales of acquired shares. The derivative summary in this filing is empty, indicating no remaining derivative positions are reported here from this specific option series after the exercises.